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Maybe a two strikes and you are out policy should also 
be applied to an intubation technique.
In the PeDI registry, the choice of airway management 
was at the discretion of the individual anaesthesiologist, 
who took into account not only patient factors, personal 
preferences and tradition of the institution, but also 
teaching factors. There is no one-size-ﬁ ts-all approach in 
paediatric anaesthesia, which makes the paediatric diﬃ  cult 
airway especially hard to study.4 Neither the success 
rates of the diﬀ erent intubation techniques (eg, direct 
laryngoscopy, video laryngoscopy, or ﬁ beroptic) nor the 
diﬀ erent operator groups (eg, trainee, consultant, or nurse 
anaesthetist) can be compared in this registry because the 
underlying patient subgroups are probably very diﬀ erent. 
For example, a patient with a known impossible direct 
laryngoscopy is more likely to be planned to receive a 
ﬁ breoptic intubation next time.  Videolaryngoscopy might 
have been chosen because direct laryngoscopy is diﬃ  cult 
or for teaching reasons to supervise a trainee. Consultants 
are more likely to intubate more diﬃ  cult patients on the 
ﬁ rst attempt compared with trainees. 
What questions remain—where to next? Which 
technique should we use in which age group and for 
which pathology? The one, we most commonly use, the 
direct laryngoscopy? The fancy one with the beautiful 
pictures, the videolaryngoscopy, but linked to longer 
tracheal intubation times and higher failure rates?5 Or the 
gold standard, the ﬁ breoptic intubation, which requires 
signiﬁ cant time and skills in case of an emergency?  What 
endpoints are important? A beautiful view or a tube in 
the trachea? If videolaryngoscopy, which one of the many 
types on the market should we use? To answers these, 
multicentre randomised controlled trials will be needed.
Data collected by PeDI could help with the planning of 
a large randomised controlled trial, and the collaboration 
established through the registry could serve as a basis 
for obtaining higher level evidence. Large randomised 
controlled trials would eliminate a lot of the bias inherent 
in registries and would provide answers about how to 
manage diﬃ  cult airways in paediatric anaesthesia. 
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In The Lancet Respiratory Medicine, Louise Pankhurst 
and colleagues1 establish the feasibility of adoption of 
whole-genome-sequencing (WGS) for routine diagnosis 
of and drug susceptibility testing for Mycobacterium 
tuberculosis in well resourced settings with a low 
tuberculosis burden. Within the context of this impressive 
study, this international team of researchers show the 
favourable performance and costs of WGS-based species 
identiﬁ cation and prediction of drug susceptibility. The 
availability of WGS led to earlier diagnosis of multidrug 
resistance than with routine laboratory diagnostics for one 
patient, and WGS also led to the identiﬁ cation of a new 
suspect transmission cluster. This eﬀ ort needed substantial 
coordination across eight participating international 
centres and development of new data and bioinformatics 
infrastructure. As such, the ﬁ ndings provide an important 
proof of principle that WGS methods can provide an 
attractive alternative to conventional approaches for 
routine diagnosis and drug susceptibility testing and 
that the information made available by routine WGS can 
improve understanding of transmission beyond what 
might be possible with molecular genetic tests.
Although Pankhurst and colleagues map a way 
forward for expanded use of WGS as a routine method 
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for diagnosis of tuberculosis, several important 
challenges exist that limit the eﬀ ect of WGS used in 
the manner described in the study. First, although 
early identiﬁ cation of drug resistance by WGS could 
have an important eﬀ ect on the treatment outcome 
for individual patients2 and on reduction of onward 
transmission of resistant strains, the approach described 
by Pankhurst and colleagues needs a positive culture 
to be obtained before DNA isolation and WGS. This 
approach is appealing because attempting to do WGS 
for detection of M tuberculosis and identiﬁ cation of 
drug resistance-associated mutations directly from 
sputum is challenging,3 and doing these tests on all 
sputum samples collected from patients who might 
have tuberculosis (not just those that exhibit growth in 
selective culture) would inﬂ ate WGS costs tremendously. 
However, a need for culture before WGS adds substantial 
delay to detection of resistance compared with comm-
ercially available tests done directly on sputum in a 
matter of hours, such as cartridge-based nucleic acid 
ampliﬁ cation tests like Cepheid Xpert MTB/RIF (Cepheid, 
Sunnyvale, CA, USA).4 In some settings, GeneXpert could 
be used for early identiﬁ cation of rifampin resistance, 
with WGS (as was done by Pankhurst and colleagues) 
providing a comprehensive picture of susceptibility, 
allowing individualisation of second-line treatment.
Second, although WGS can play a part in identiﬁ cation 
or exclusion of transmission between individuals and 
can, in some circumstances, suggest directionality 
of transmission, little evidence exists that routine 
use of genotyping has helped to curb transmission,5 
although ruling out of transmission has probably 
averted unnecessary contact tracing eﬀ orts. Although 
we are optimistic that improved characterisation 
of transmission patterns will ultimately result from 
incorporation of WGS data into transmission studies, 
whether this information can be eﬀ ectively used to 
avert transmission events that would have occurred in 
the absence of such information remains to be seen.
Third, we note that Pankhurst and colleagues included 
eight international study sites with state-of-the-art 
facilities and low throughput of samples; across these 
sites, 171 M tuberculosis-positive samples were identiﬁ ed 
with WGS. As Pankhurst and colleagues note, scaling 
up of WGS technologies to much larger numbers of 
samples within centres with less advanced infrastructure 
than those in this study is challenging because of the 
need for sequencing and data infrastructure along with 
bioinformatics expertise.
We believe that this study represents a major step 
forward in the eﬀ ort to use WGS as a method for routine 
diagnosis and are optimistic that WGS infrastructure will 
have positive eﬀ ects beyond diagnosis. Methods to infer 
patterns of transmission from sequence data are being 
improved, but use of these methods to inform realtime 
tuberculosis control will need more robust analytical 
methods than those at present and systems allowing 
rapid dissemination of WGS data and associated 
metadata to public health authorities.6–9 If eﬀ orts to link 
WGS data to de-identiﬁ ed metadata and make these 
available are successful,10,11 the scientiﬁ c community 
will be able to expand the already growing database 
relating sequences to resistance proﬁ les and continue to 
improve prediction of resistance from sequences.12–14
The costs of sequencing are likely to continue to 
decrease, and the capabilities of sequencing-based 
technologies will probably continue to improve. Both 
of these factors make adoption of WGS infrastructure 
appealing beyond the slight cost beneﬁ t reported in 
this study. Exciting approaches to the challenge of 
sequencing directly from sputum (without waiting 
for culture) have already yielded promising results.3,15 
These approaches, together with deep sequencing, 
could improve detection of minority variants in sputum, 
further improving characterisation and understanding 
of both transmission and resistance and needing 
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In principle, WGS methods oﬀ er the ability to 
customise treatment regimens on the basis of rapidly 
obtained knowledge of individual resistance proﬁ les 
to understand when and where transmission is taking 
place and characterise the acquisition and transmission 
of drug resistance in real time. Pankhurst and colleagues 
have shown a proof of principle that a move to WGS 
technologies is feasible in high-income settings; 
ultimately, expanded adoption of WGS, if eﬀ ectively 
combined with data deposition and sharing, could 
be a major step towards realisation of the promised 
beneﬁ ts of sequencing technologies for improvement of 
understanding and control of tuberculosis.
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What if we made stratiﬁ ed medicine work for patients? 
Stratiﬁ ed medicine is the ultimate medical advance—
the targeting of medicines and other interventions 
according to biological characteristics of subgroups of 
patients. The UK Medical Research Council promises 
that “Ultimately stratiﬁ ed medicine will ensure that the 
right patient gets the right treatment at the right time”1 
and the Academy of Medical Sciences has argued that it 
will “revolutionise the treatment of disease”.2 We seek 
to expand this debate by moving beyond the narrow 
conﬁ nes of biomarkers and genomics and exploring 
what genuinely patient-focused stratiﬁ ed medicine 
might look like.
Stratiﬁ ed medicines are a serious challenge to 
evidence-based medicine. Even the best evidence 
oﬀ ers a one size ﬁ ts all solution. Research tells us 
which drugs have proven safe and eﬀ ective for a 
particular disease, but crucially—as physicians are 
quick to point out—not whether they will work for 
a particular patient. Medicines are not eﬀ ective 
for everyone. Some people will experience adverse 
reactions while others will not. Sometimes medicines 
work brilliantly, but in other cases, they do not. Rather 
than waste money and time, and cause unnecessary 
suﬀ ering, it would be preferable to give medicines only 
to those people who will beneﬁ t from them. This is the 
challenge, and the promise, of stratiﬁ ed medicine.
Thus far much of the debate and exploration of the 
potential of stratiﬁ ed medicine has been concerned 
with identifying genetically deﬁ ned population 
subgroups who might beneﬁ t from particular 
interventions. This has proven incredibly useful: 
advances in developing treatments for hepatitis C, 
based on the use of biomarkers, have allowed targeting 
of interventions for patients who can beneﬁ t. However, 
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